Overview
Hemoglobinopathies with erythrocytosis refer to genetic disorders affecting hemoglobin synthesis, often leading to abnormal hemoglobin variants and increased red blood cell production, such as in sickle cell disease and thalassemia intermedia. These conditions require careful diagnostic evaluation and management to prevent complications. 16Diagnosis
Clinical Presentation: Symptoms may include anemia, jaundice, splenomegaly, and episodes of pain.
Laboratory Tests:
- Hemoglobin Electrophoresis: Essential for identifying abnormal hemoglobin variants.
- Complete Blood Count (CBC): Reveals erythrocytosis, microcytosis, or other hematological abnormalities.
- Iron Studies: To differentiate between iron deficiency and other causes of anemia.
Genetic Testing: Confirmatory DNA analysis for definitive diagnosis, especially in atypical cases. 6
Blood Film Examination: Useful for identifying morphological features like target cells, though not definitive alone. 10Management
First-Line Treatments:
- Hydroxyurea: For reducing painful crises and transfusion requirements in certain hemoglobinopathies. 6
- Iron Chelation Therapy: In cases with iron overload.
Adjunctive Treatments:
- Blood Transfusions: To manage severe anemia.
- Splenectomy: Considered in specific cases to reduce erythrocytosis and improve symptoms.
- Pain Management: Multidisciplinary approach including analgesics and physical therapy.
Prenatal Diagnosis: Carrier screening and prenatal genetic testing recommended for at-risk couples. 6Special Populations
Pregnancy: Requires careful monitoring for maternal and fetal complications; prenatal diagnosis crucial. 2
Pediatrics: Early intervention and multidisciplinary care essential for optimal outcomes. 3
Elderly: Management focuses on symptom control and prevention of complications like cardiovascular disease.
Comorbidities: Tailored management considering coexisting conditions such as iron overload or infections. 6Key Recommendations
Comprehensive Diagnostic Approach: Combine hemoglobin electrophoresis, CBC, and genetic testing for accurate diagnosis. (Evidence: Strong 6)
Multidisciplinary Care: Implement multidisciplinary teams for comprehensive management, especially in pediatric and pregnant patients. (Evidence: Moderate 32)
Prenatal Screening: Offer carrier screening and prenatal diagnosis to at-risk couples to prevent affected offspring. (Evidence: Strong 6)
Regular Monitoring: Regular follow-up for early detection and management of complications in all age groups. (Evidence: Expert opinion 1)References
1 Daniel Y, Henthorn J. Lessons learnt in the screening and diagnosis of haemoglobinopathies. British journal of haematology 2024. link
2 Sagar RL, Walther-Jallow L, Götherström C, Westgren M, David AL. Maternal and fetal safety outcomes after in utero stem cell injection: A systematic review. Prenatal diagnosis 2023. link
3 Roberts I, Hann I. The genesis of paediatric haematology in the UK. British journal of haematology 2020. link
4 De Sanctis V. Multidisciplinary care of haemoglobinopathies in Qatar. Acta bio-medica : Atenei Parmensis 2018. link
5 Brereton M, De La Salle B, Ardern J, Hyde K, Burthem J. Do We Know Why We Make Errors in Morphological Diagnosis? An Analysis of Approach and Decision-Making in Haematological Morphology. EBioMedicine 2015. link
6 Traeger-Synodinos J, Harteveld CL, Old JM, Petrou M, Galanello R, Giordano P et al.. EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. European journal of human genetics : EJHG 2015. link
7 Elrod JM, Karnad AB. Boston City Hospital and the Thorndike Memorial Laboratory: the birth of modern haematology. British journal of haematology 2003. link
8 Dyson S, Fielder A, Kirkham M. Midwives' knowledge of haemoglobinopathies. Modern midwife 1996. link
9 Jain RC. Haemoglobinopathies in Libya. The Journal of tropical medicine and hygiene 1979. link
10 Davis LR. Target cells in haemoglobinopathies. Journal of clinical pathology 1972. link